Publicacións en colaboración con investigadores/as de University of Michigan Medical School (24)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Targeting DNA2 overcomes metabolic reprogramming in multiple myeloma

    Nature Communications, Vol. 15, Núm. 1

  4. The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models

    Neuro-Oncology, Vol. 26, Núm. 8, pp. 1509-1525

2023

  1. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    Blood, Vol. 141, Núm. 9, pp. 1047-1059

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Regulation and role of the PP2A-B56 holoenzyme family in cancer

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1878, Núm. 5

  4. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy (Nature Medicine, (2022), 28, 3, (557-567), 10.1038/s41591-022-01696-4)

    Nature Medicine

  2. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

    Nature Medicine, Vol. 28, Núm. 3, pp. 557-567

2021

  1. Hematopoiesis under telomere attrition at the single-cell resolution

    Nature Communications, Vol. 12, Núm. 1

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

2016

  1. Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: A retrospective multicohort analysis

    Journal of Clinical Oncology, Vol. 34, Núm. 21, pp. 2468-2477

  2. miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation

    Journal of Molecular and Cellular Cardiology, Vol. 99, pp. 162-173

2015

  1. Characterization of large structural genetic mosaicism in human autosomes

    American Journal of Human Genetics, Vol. 96, Núm. 3, pp. 487-497

  2. Consensus nomenclature for CD8+ T cell phenotypes in cancer

    OncoImmunology, Vol. 4, Núm. 4

2014

  1. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma

    Cancer Cell, Vol. 25, Núm. 6, pp. 735-747

2013

  1. A prognostic DNA methylation signature for stage I non-small-cell lung cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 32, pp. 4140-4147

2010

  1. Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research

    American Journal of Infection Control, Vol. 38, Núm. 4, pp. 251-258

2003

  1. Intrapulmonary expression of macrophage inflammatory protein 1α (CCL3) induces neutrophil and NK cell accumulation and stimulates innate immunity in murine bacterial pneumonia

    Infection and Immunity, Vol. 71, Núm. 3, pp. 1306-1315